نتایج جستجو برای: dasatinib

تعداد نتایج: 1954  

2010
Jiannong Li Uwe Rix Bin Fang Yun Bai Arthur Edwards Jacques Colinge Keiryn L. Bennett Jingchun Gao Lanxi Song Steven Eschrich Giulio Superti-Furga John Koomen Eric B. Haura

We describe a strategy for comprehending signaling pathways that are active in lung cancer cells and that are targeted by dasatinib using chemical proteomics to identify direct interacting proteins combined with immunoaffinity purification of tyrosine-phosphorylated peptides corresponding to activated tyrosine kinases. We identified nearly 40 different kinase targets of dasatinib. These include...

2011
Jan K Hennigs Gunhild Keller Hans Jörg Baumann Friedemann Honecker Stefan Kluge Carsten Bokemeyer Tim H Brümmendorf Hans Klose

BACKGROUND Pulmonary hypertension (PH) is a life-threatening disease with poor prognosis. Encouraging efforts have been made to target the main vasoproliferative aspects of the disease. Promising emerging therapeutics are tyrosine kinase inhibitors such as imatinib. CASE PRESENTATION Here, we discuss the relevance of previously published cases and add another well-characterised patient who de...

Journal: :Blood 2009
Alfonso Quintás-Cardama Xin Han Hagop Kantarjian Jorge Cortes

Dasatinib is associated with increased risk of bleeding among patients with chronic myeloid leukemia, even in the absence of thrombocytopenia, suggesting the presence of a hemostatic defect. We tested platelet aggregation in 91 patients with chronic myeloid leukemia in chronic phase either off-therapy (n = 4) or receiving dasatinib (n = 27), bosutinib (n = 32), imatinib (n = 19), or nilotinib (...

2014
Edna Gordian Jiannong Li Yuri Pevzner Melanie Mediavilla-Varela Kimberly Luddy Kim Ohaegbulam Kenyon G. Daniel Eric B. Haura Teresita Muñoz-Antonia

Lung cancer is the second most common cancer and the leading cause of cancer-related deaths. Despite recent advances in the development of targeted therapies, patients with advanced disease remain incurable, mostly because metastatic non-small cell lung carcinomas (NSCLC) eventually become resistant to tyrosine kinase inhibitors (TKIs). Kinase inhibitors have the potential for target promiscuit...

2013
DUSKA SEPAROVIC PAUL BREEN NITHIN B. BOPPANA ERIC VAN BUREN NICHOLAS JOSEPH JACQUELINE M. KRAVEKA MEHRDAD RAHMANIYAN LI LI TATYANA I. GUDZ ALICJA BIELAWSKA AIPING BAI JACEK BIELAWSKI JASON S. PIERCE MLADEN KORBELIK

Photodynamic therapy (PDT) is not always effective as an anticancer treatment, therefore, PDT is combined with other anticancer agents for improved efficacy. The combination of dasatinib and PDT with the silicone phthalocyanine photosensitizer Pc 4 was assessed for increased killing of SCCVII mouse squamous cell carcinoma cells, a preclinical model of head and neck squamous cell carcinoma, usin...

Journal: :Haematologica 2007
Karoline V Gleixner Matthias Mayerhofer Karoline Sonneck Alexander Gruze Puchit Samorapoompichit Christian Baumgartner Francis Y Lee Karl J Aichberger Paul W Manley Doriano Fabbro Winfried F Pickl Christian Sillaber Peter Valent

BACKGROUND AND OBJECTIVES In a majority of all patients with systemic mastocytosis (SM) including those with mast cell leukemia (MCL), neoplastic mast cells (MC) display the D816V-mutated variant of KIT. The respective oncoprotein, KIT D816V, exhibits constitutive tyrosine kinase (TK) activity and has been implicated in malignant cell growth. Therefore, several attempts have been made to identi...

2015
Kevin Marley Justine Gullaba Bernard Seguin Howard B. Gelberg Stuart C. Helfand

BACKGROUND This investigation sought to elucidate the relationship between hepatocyte growth factor (HGF)-induced metastatic behavior and the tyrosine kinase inhibitors (TKIs) crizotinib and dasatinib in canine osteosarcoma (OS). Preliminary evidence of an apparent clinical benefit from adjuvant therapy with dasatinib in four dogs is described. METHODS The inhibitors were assessed for their a...

Journal: :Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2016
Liquan Gao Hao Liu Xianlei Sun Duo Gao Chenran Zhang Bing Jia Zhaohui Zhu Fan Wang Zhaofei Liu

UNLABELLED Noninvasive, real-time, quantitative measurement of key biomarkers associated with cancer therapeutic interventions could provide a better understanding of cancer biology. We investigated in this study whether incorporating multiple molecular imaging approaches could be used to guide dasatinib anti-Src therapy and aid in the rational design of a combination therapy regimen. METHODS...

2015
Henrik Hjorth-Hansen Leif Stenke Stina Söderlund Arta Dreimane Hans Ehrencrona Tobias Gedde-Dahl Bjørn Tore Gjertsen Martin Höglund Perttu Koskenvesa Kourosh Lotfi Waleed Majeed Berit Markevärn Lotta Ohm Ulla Olsson-Strömberg Kari Remes Merja Suominen Bengt Simonsson Kimmo Porkka Satu Mustjoki Johan Richter

We randomised 46 newly diagnosed patients with chronic myeloid leukaemia (median age 56) to receive dasatinib 100 mg QD or imatinib 400 mg QD and report outcome as an intention-to-treat analysis with 36 months follow-up. Early cytogenetic and molecular responses were superior in the dasatinib group, with a tendency that imatinib patients caught up with time. For instance, MR(3.0) was reached at...

Journal: :Molecular cancer therapeutics 2016
Rajendar K Mittapalli Alexander H Chung Karen E Parrish Donna Crabtree Kyle G Halvorson Guo Hu William F Elmquist Oren J Becher

Dasatinib is a multikinase inhibitor in clinical trials for glioma, and thus far has failed to demonstrate significant efficacy. We investigated whether the ABC efflux transporters ABCG2 and ABCB1 expressed in the blood-brain barrier (BBB), are limiting the efficacy of dasatinib in the treatment of glioma using genetic and pharmacologic approaches. We utilized a genetic brainstem glioma mouse m...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید